Join our daily newsletter At The Bell to receive exclusive market insights
- Island Pharmaceuticals (ILA) is granted an Australian patent for its method of treating mosquito-borne viruses
- The patent is entitled “Method of Viral Inhibition” and remains valid until April 2034
- This marks the third patent granted to Island Pharmaceuticals within the past year, adding to an estate that includes patents granted in the US, Singapore and Brazil
- Island Pharmaceuticals is up 1.47 per cent, trading at 34.5 cents
Island Pharmaceuticals (ILA) has been granted a patent for its method of treating mosquito-borne viruses.
The patent, entitled “Method of Viral Inhibition”, was granted by IP Australia and expires on April 16 2034. The patent covers a method of treating or preventing dengue virus and similar virus infections using Island’s lead product, ISLA-101.
The company says its drug has a well-known safety profile and is now being repurposed for mosquito-borne viruses.
Dengue affects a large portion of Asia, the South Pacific, South America, Central America and Africa, infecting around 390 million people each year. Without access to medical care, dengue fever has a significant mortality rate.
CEO of Island Pharmaceuticals, Dr David Foster, says the company is excited about being granted this patent, which supports the applicability of the treatment for different mosquito-related viruses.
“This patent further protects our lead program, which is critical as we advance towards the commencement of clinical trials at the end of this year.”
This marks the third patent granted to Island Pharma within the past year, adding to an estate that includes patents granted in the US, Singapore and Brazil.
Island Pharmaceuticals was up 1.47 per cent, trading at 34.5 cents at 2:44 pm AEST.
